The University of Chicago Header Logo

Connection

Ralph Weichselbaum to Head and Neck Neoplasms

Back to Details
This is a "connection" page, showing publications Ralph Weichselbaum has written about Head and Neck Neoplasms.
Ralph Weichselbaum
Connection Strength
4.355
Head and Neck Neoplasms
  1. Comparison of 3D confromal radiotherapy and intensity modulated radiotherapy with or without simultaneous integrated boost during concurrent chemoradiation for locally advanced head and neck cancers. PLoS One. 2014; 9(4):e94456.
    View in: PubMed
    Score: 0.250
  2. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.184
  3. More on cetuximab in head and neck cancer. N Engl J Med. 2007 Nov 22; 357(21):2201-2; author reply 2202-3.
    View in: PubMed
    Score: 0.160
  4. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.094
  5. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res. 2000 Feb; 6(2):737-42.
    View in: PubMed
    Score: 0.093
  6. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.088
  7. Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer. Clin Cancer Res. 2019 03 15; 25(6):1795-1808.
    View in: PubMed
    Score: 0.086
  8. Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin-chimeric protein. Cancer Res. 1998 Aug 01; 58(15):3215-20.
    View in: PubMed
    Score: 0.084
  9. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.077
  10. DNA double-strand break rejoining rates, inherent radiation sensitivity and human tumour response to radiotherapy. Br J Cancer. 1996 Jul; 74(1):37-42.
    View in: PubMed
    Score: 0.073
  11. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr; 2(4):755-62.
    View in: PubMed
    Score: 0.072
  12. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
    View in: PubMed
    Score: 0.069
  13. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):47-52.
    View in: PubMed
    Score: 0.068
  14. Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope. 1995 Jan; 105(1):97-101.
    View in: PubMed
    Score: 0.066
  15. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81.
    View in: PubMed
    Score: 0.065
  16. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
    View in: PubMed
    Score: 0.065
  17. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41.
    View in: PubMed
    Score: 0.064
  18. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112.
    View in: PubMed
    Score: 0.064
  19. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncol. 2014 Sep; 50(9):825-31.
    View in: PubMed
    Score: 0.064
  20. Radiation therapy in head and neck cancer: indications and limitations. Semin Oncol. 1994 Jun; 21(3):296-303.
    View in: PubMed
    Score: 0.063
  21. Effect of postradiotherapy neck dissection on nonregional disease sites. JAMA Otolaryngol Head Neck Surg. 2014 Jan; 140(1):12-21.
    View in: PubMed
    Score: 0.061
  22. Chromosome changes characterizing in vitro response to radiation in human squamous cell carcinoma lines. Cancer Res. 1993 Nov 15; 53(22):5542-7.
    View in: PubMed
    Score: 0.061
  23. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
    View in: PubMed
    Score: 0.060
  24. Racial parities in outcomes after radiotherapy for head and neck cancer. Cancer. 2014 Jan 15; 120(2):244-52.
    View in: PubMed
    Score: 0.060
  25. Measurable impact: multimodality therapy of head and neck cancer. Int J Radiat Oncol Biol Phys. 1993 Sep 30; 27(2):481-2.
    View in: PubMed
    Score: 0.060
  26. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):52-8.
    View in: PubMed
    Score: 0.060
  27. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993 Aug 15; 53(16):3667-9.
    View in: PubMed
    Score: 0.060
  28. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.056
  29. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992 Sep 01; 52(17):4832-6.
    View in: PubMed
    Score: 0.056
  30. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
    View in: PubMed
    Score: 0.055
  31. Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas. J Natl Cancer Inst. 1992 May 20; 84(10):793-7.
    View in: PubMed
    Score: 0.055
  32. The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines. Oncology. 1992; 49(6):454-60.
    View in: PubMed
    Score: 0.053
  33. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
    View in: PubMed
    Score: 0.053
  34. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
    View in: PubMed
    Score: 0.053
  35. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
    View in: PubMed
    Score: 0.052
  36. Recent advances in radiation therapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):635-55.
    View in: PubMed
    Score: 0.052
  37. Radiotherapy with concomitant chemotherapy for head and neck cancer. Hematol Oncol Clin North Am. 1991 Aug; 5(4):753-67.
    View in: PubMed
    Score: 0.052
  38. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
    View in: PubMed
    Score: 0.052
  39. Radiobiological characterization of head and neck and sarcoma cells derived from patients prior to radiotherapy. Int J Radiat Oncol Biol Phys. 1990 Aug; 19(2):313-9.
    View in: PubMed
    Score: 0.048
  40. A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
    View in: PubMed
    Score: 0.048
  41. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol. 2010 Apr 01; 6(4):e1000730.
    View in: PubMed
    Score: 0.047
  42. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck. 1989 Sep-Oct; 11(5):437-42.
    View in: PubMed
    Score: 0.045
  43. Radioresistant tumor cell lines derived from head and neck radiation failures. Head Neck. 1989 Jul-Aug; 11(4):343-8.
    View in: PubMed
    Score: 0.045
  44. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
    View in: PubMed
    Score: 0.045
  45. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys. 1988 Sep; 15(3):575-9.
    View in: PubMed
    Score: 0.042
  46. Southern analysis of human head and neck cancer cells for homologous sequences using yeast gamma repair genes. J Surg Oncol. 1988 Aug; 38(4):257-60.
    View in: PubMed
    Score: 0.042
  47. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.041
  48. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
    View in: PubMed
    Score: 0.036
  49. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.036
  50. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A. 1986 Apr; 83(8):2684-8.
    View in: PubMed
    Score: 0.036
  51. Multidisciplinary treatment of advanced squamous carcinoma of the head and neck. Semin Oncol. 1985 Dec; 12(4 Suppl 6):71-8.
    View in: PubMed
    Score: 0.035
  52. Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. Cancer. 1985 May 01; 55(9 Suppl):2149-55.
    View in: PubMed
    Score: 0.034
  53. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
    View in: PubMed
    Score: 0.033
  54. Cellular X-ray repair parameters of early passage squamous cell carcinoma lines derived from patients with known responses to radiotherapy. Br J Cancer. 1984 May; 49(5):595-601.
    View in: PubMed
    Score: 0.031
  55. Radiobiologic research for head and neck cancer therapy. Therapeutic implications. Arch Otolaryngol. 1983 Dec; 109(12):792-6.
    View in: PubMed
    Score: 0.030
  56. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.030
  57. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.029
  58. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.029
  59. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer. 2002 Aug; 38(12):1585-92.
    View in: PubMed
    Score: 0.028
  60. Chemical modulation of the hypoxic fraction in the treatment of head and neck cancer. Ann Otol Rhinol Laryngol. 1982 Jul-Aug; 91(4 Pt 1):461-4.
    View in: PubMed
    Score: 0.028
  61. Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1982 May; 8(5):909-13.
    View in: PubMed
    Score: 0.027
  62. Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. Int J Oncol. 2001 Oct; 19(4):833-5.
    View in: PubMed
    Score: 0.026
  63. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.025
  64. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
    View in: PubMed
    Score: 0.024
  65. Volumetric visualization of head and neck CT data for treatment planning. Int J Radiat Oncol Biol Phys. 1999 Jun 01; 44(3):693-703.
    View in: PubMed
    Score: 0.022
  66. The contribution of DNA ploidy to radiation sensitivity in human tumour cell lines. Br J Cancer. 1999 Feb; 79(5-6):744-7.
    View in: PubMed
    Score: 0.022
  67. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
    View in: PubMed
    Score: 0.022
  68. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
    View in: PubMed
    Score: 0.021
  69. Initial adjuvant weekly high dose methotrexate with leucovorin rescue in advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1978 Jul-Aug; 4(7-8):671-4.
    View in: PubMed
    Score: 0.021
  70. Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope. 1978 Apr; 88(4):632-8.
    View in: PubMed
    Score: 0.021
  71. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.020
  72. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
    View in: PubMed
    Score: 0.019
  73. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
    View in: PubMed
    Score: 0.019
  74. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
    View in: PubMed
    Score: 0.019
  75. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
    View in: PubMed
    Score: 0.018
  76. Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995; 74:173-98.
    View in: PubMed
    Score: 0.016
  77. Combined modality therapy of head and neck cancer. Semin Oncol. 1994 Jun; 21(3):349-58.
    View in: PubMed
    Score: 0.016
  78. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
    View in: PubMed
    Score: 0.016
  79. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
    View in: PubMed
    Score: 0.014
  80. Head and neck cancer. N Engl J Med. 1993 Jan 21; 328(3):184-94.
    View in: PubMed
    Score: 0.014
  81. Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
    View in: PubMed
    Score: 0.014
  82. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
    View in: PubMed
    Score: 0.014
  83. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
    View in: PubMed
    Score: 0.014
  84. Prognostic factors in advanced head and neck cancer patients undergoing multimodality therapy. Otolaryngol Head Neck Surg. 1991 Jul; 105(1):62-73.
    View in: PubMed
    Score: 0.013
  85. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15.
    View in: PubMed
    Score: 0.012
  86. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct; 9(10):2814-24.
    View in: PubMed
    Score: 0.012
  87. Prediction of the radiation sensitivity of human squamous cell carcinoma cells using DNA filter elution. Radiat Res. 1990 Jul; 123(1):1-6.
    View in: PubMed
    Score: 0.012
  88. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990 May; 8(5):911-34.
    View in: PubMed
    Score: 0.012
  89. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
    View in: PubMed
    Score: 0.012
  90. Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol. 1989 Jul; 7(7):838-45.
    View in: PubMed
    Score: 0.011
  91. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
    View in: PubMed
    Score: 0.011
  92. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
    View in: PubMed
    Score: 0.011
  93. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
    View in: PubMed
    Score: 0.010
  94. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
    View in: PubMed
    Score: 0.010
  95. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
    View in: PubMed
    Score: 0.010
  96. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20.
    View in: PubMed
    Score: 0.009
  97. The syndrome of inappropriate antidiuretic hormone secretion associated with induction chemotherapy for squamous cell carcinoma of the head and neck. J Surg Oncol. 1986 Jul; 32(3):150-2.
    View in: PubMed
    Score: 0.009
  98. Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93.
    View in: PubMed
    Score: 0.009
  99. Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate. Arch Otolaryngol. 1984 Apr; 110(4):241-5.
    View in: PubMed
    Score: 0.008
  100. Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope. 1984 Apr; 94(4):451-54.
    View in: PubMed
    Score: 0.008
  101. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):787-91.
    View in: PubMed
    Score: 0.007
  102. Role of chemotherapy in the multidisciplinary approach to advanced head and neck cancer: potentials and problems. Ann Otol Rhinol Laryngol. 1981 Sep-Oct; 90(5 Pt 1):506-11.
    View in: PubMed
    Score: 0.007
  103. Improved survival for patients with advanced carcinoma of the head and neck treated with methotrexate-leucovorin prior to definitive radiotherapy or surgery. Laryngoscope. 1981 Jul; 91(7):1181-90.
    View in: PubMed
    Score: 0.006
  104. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
    View in: PubMed
    Score: 0.006
  105. Chemotherapy for advanced carcinoma of the head and neck. A clinical update. Arch Otolaryngol. 1981 Apr; 107(4):237-41.
    View in: PubMed
    Score: 0.006
  106. The differential diagnosis of the mass in the neck. A fresh look. Laryngoscope. 1981 Jan; 91(1):140-5.
    View in: PubMed
    Score: 0.006
  107. Predefinitive and postdefinitive chemotherapy for locally advanced squamous carcinoma of the head and neck. Laryngoscope. 1979 Apr; 89(4):573-81.
    View in: PubMed
    Score: 0.006
  108. Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 1991 Apr; 20(4):733-8.
    View in: PubMed
    Score: 0.003
  109. A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. Sel Cancer Ther. 1989; 5(3):137-45.
    View in: PubMed
    Score: 0.003
  110. Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment. Br J Cancer. 1987 Mar; 55(3):245-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.